Cargando…
Pancreatic β‐cell fate in subjects with COVID‐19
Two recent reports denoted the potential of SARS‐CoV‐2 to directly infect β‐cells and the possible fate of β‐cells under COVID‐19. The fight against SARS‐CoV‐2 will continue to develop more effective therapeutic strategies for diabetes. [Image: see text]
Autor principal: | Shirakawa, Jun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8668054/ https://www.ncbi.nlm.nih.gov/pubmed/34529355 http://dx.doi.org/10.1111/jdi.13671 |
Ejemplares similares
-
Potential linkage between dipeptidyl peptidase‐4 inhibitor use and the risk of pancreatitis/pancreatic cancer
por: Shirakawa, Jun, et al.
Publicado: (2020) -
Glucose‐ or insulin resistance‐mediated β‐cell replication: PKCζ integrates the proliferative signaling
por: Shirakawa, Jun, et al.
Publicado: (2016) -
Selective and sequential loss of transcriptional factors: A hallmark of β‐cell failure in type 2 diabetes?
por: Shirakawa, Jun, et al.
Publicado: (2014) -
Following the Fate of the Failing β-Cell: New Insights From First-Phase Insulin Responses
por: Williams, Alistair J.K., et al.
Publicado: (2013) -
The Clonal Fate of Live Cells
por: Wang, Wei, et al.
Publicado: (2017)